WS016, a novel potassium binder: safety, tolerability and pharmacodynamics in first-in-human phase 1 healthy volunteer study

被引：0

作者：

Zhang, Faming ^{[1
]}

Song, Aiyun ^{[1
]}

Fu, Min ^{[1
]}

Zhou, Youcheng ^{[1
]}

Hu, Minglong ^{[1
]}

机构：

[1] Waterstone Pharmaceut Wuhan Co LTD, Wuhan, Peoples R China

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

2341

引用

页码：I1149 / I1151

页数：3

共 50 条

[1] WS016, a novel potassium binder: safety, tolerability and pharmacodynamics in first-in-human phase 1 healthy volunteer study
Zhang, Faming
Song, Aiyun
Fu, Min
Zhou, Youcheng
Hu, Minglong
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
[2] Tolerability and kinetics of SYNB1020 in a Phase 1, first-in-Human, healthy adult volunteer study
Puurunen, M.
Denney, W. S.
Blankstein, L.
Goldwater, R.
Parsons, T.
Millet, Y.
Kurtz, C.
Brennan, A.
JOURNAL OF HEPATOLOGY, 2018, 68 : S737 - S737
[3] A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
Ahmadi, Ali R.
Atiee, George
Chapman, Bart
Reynolds, Laurie
Sun, John
Cameron, Andrew M.
Wesson, Russell N.
Burdick, James F.
Sun, Zhaoli
CELL REPORTS MEDICINE, 2023, 4 (09)
[4] Safety and Efficacy of WS016 in Patients with Hyperkalemia in China from a Phase 2 Study
Song Aiyun
Zuo Li
Zhao Jianrong
Ji Zhen Hua
Peng Qingfeng
Xu Wen Chuan
Tian, N. A.
Zhang Qinghong
Xue Xianjun
Huang Xinzhong
Sun Changyou
Niu Jianying
Yan Fan
Zhang Faming
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
[5] Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab First-in-Human Healthy Volunteer Trial
Voors-Pette, Christine
Lebozec, Kristell
Dogterom, Peter
Jullien, Laurie
Billiald, Philippe
Ferlan, Pauline
Renaud, Lionel
Favre-Bulle, Olivier
Avenard, Gilles
Machacek, Matthias
Pletan, Yannick
Jandrot-Perrus, Martine
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39 (05) : 956 - 964
[6] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Akizawa, Tadao
Shimazaki, Ryutaro
Shiramoto, Masanari
Fukagawa, Masafumi
CLINICAL DRUG INVESTIGATION, 2018, 38 (10) : 945 - 954
[7] Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study
Tadao Akizawa
Ryutaro Shimazaki
Masanari Shiramoto
Masafumi Fukagawa
Clinical Drug Investigation, 2018, 38 : 945 - 954
[8] A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects
Gul, Ahmet
Ulker, Sibel
Senturk, Recep Selim
Turk, Ugur Onsel
Gurgun, Cemil
Lavrovsky, Yan
Samsonov, Mikhail
Ozen, Sebnem
Altinel, Serdar
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[9] First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults
Mammen, Mammen P.
Armas, Danielle
Hughes, Frank H.
Hopkins, Andrew M.
Fisher, Cindy L.
Resch, Pamela A.
Rusalov, Denis
Sullivan, Sean M.
Smith, Larry R.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (11)
[10] Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects
Geven, Christopher
van Lier, Dirk
Blet, Alice
Peelen, Roel
ten Elzen, Bas
Mebazaa, Alexandre
Kox, Matthijs
Pickkers, Peter
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (09) : 2129 - 2141

← 1 2 3 4 5 →